The National Health Surveillance Agency (Anvisa) approved new indications for the drug sacituzumab govitecan in the treatment of breast cancer. The measure expands the situations in which the medication can be used by adult patients with locally advanced or metastatic disease.
Sacituzumab govitecan is a medication developed to fight tumor cells and already had previous approvals for other indications in breast cancer treatment. With the new approval, more patients will have access to therapy at different stages of the disease.
The decision by the Brazilian regulatory agency allows physicians to prescribe the medication in additional clinical contexts, expanding the therapeutic options available to patients with more advanced forms of the disease.
The approval represents an evolution in breast cancer treatment in Brazil, offering an additional therapeutic alternative for adult patients facing the disease at more advanced stages or with metastasis.
